TY - JOUR
T1 - Clinical integration of next generation sequencing
T2 - Coverage and reimbursement challenges
AU - Deverka, Patricia A.
AU - Dreyfus, Jennifer C.
N1 - Publisher Copyright:
© 2014 American Society of Law, Medicine & Ethics, Inc. 42 s1 Fall 2014 10.1111/jlme.12160 Symposium Articles Symposium Articles © 2014 American Society of Law, Medicine & Ethics, Inc.
PY - 2014/9/1
Y1 - 2014/9/1
N2 - Public and private payers face complex decisions regarding whether, when, and how to cover and reimburse for next generation sequencing (NGS)-based tests. Yet a predictable reimbursement pathway is critical both for patient access and incentives to provide the market with better clinical evidence. While preliminary data suggests that payers will use similar evidentiary standards as those used to evaluate established molecular diagnostic tests, the volume and complexity of information generated by NGS raises a host of additional considerations for payers that are specific to this technology.
AB - Public and private payers face complex decisions regarding whether, when, and how to cover and reimburse for next generation sequencing (NGS)-based tests. Yet a predictable reimbursement pathway is critical both for patient access and incentives to provide the market with better clinical evidence. While preliminary data suggests that payers will use similar evidentiary standards as those used to evaluate established molecular diagnostic tests, the volume and complexity of information generated by NGS raises a host of additional considerations for payers that are specific to this technology.
UR - http://www.scopus.com/inward/record.url?scp=84907875064&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84907875064&partnerID=8YFLogxK
U2 - 10.1111/jlme.12160
DO - 10.1111/jlme.12160
M3 - Article
C2 - 25298289
AN - SCOPUS:84907875064
VL - 42
SP - 22
EP - 41
JO - Nursing law & ethics,
JF - Nursing law & ethics,
SN - 1073-1105
IS - s1
ER -